Cargando…

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban

BACKGROUND AND OBJECTIVES: The effects of age and sex on apixaban pharmacokinetics and pharmacodynamics were studied. METHODS: This was an open-label, single-dose, 2 × 2 factorial study. Healthy young (aged 18–40 years) and elderly (aged ≥65 years) male and female subjects received a single oral 20 ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frost, Charles E., Song, Yan, Shenker, Andrew, Wang, Jessie, Barrett, Yu Chen, Schuster, Alan, Harris, Stuart I., LaCreta, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449375/ https://www.ncbi.nlm.nih.gov/pubmed/25573421 http://dx.doi.org/10.1007/s40262-014-0228-0

Ejemplares similares

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
por: Byon, Wonkyung, et al.
Publicado: (2019)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery
por: Leil, T A, et al.
Publicado: (2014)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
por: Wang, Xiaoli, et al.
Publicado: (2013)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
por: Merali, Samira J., et al.
Publicado: (2023)

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban
por: Zaky, Mohamed F., et al.
Publicado: (2023)

Alfaxalone population pharmacokinetics in the rat: Model application for pharmacokinetic and pharmacodynamic design in inbred and outbred strains and sexes
por: White, Kate, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
por: Pagan, Fernando L., et al.
Publicado: (2019)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
por: Badreldin, Hisham A, et al.
Publicado: (2020)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects
por: Garimella, Tushar, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion
por: Cirincione, Brenda, et al.
Publicado: (2017)

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
por: Herrera, Noelle D., et al.
Publicado: (2021)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
por: Jaber, Ali, et al.
Publicado: (2022)

Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
por: Fung, Winston Wing-Shing, et al.
Publicado: (2023)

Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
por: Hsu, Cheng‐Pang, et al.
Publicado: (2022)

Critical Analysis of Apixaban Dose Adjustment Criteria
por: Vu, Anh, et al.
Publicado: (2021)

The contribution of apixaban renal clearance to total clearance
por: Frost, Charles, et al.
Publicado: (2015)

The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
por: Lawrence, Matthew J., et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
por: Le Louedec, Félicien, et al.
Publicado: (2020)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses
por: Gold, Jenifer R., et al.
Publicado: (2022)

The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
por: Smith, Joe S., et al.
Publicado: (2023)

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects
por: Li, Haiyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5iiolv37kn3o9neddlk8ulk1pu